These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

992 related articles for article (PubMed ID: 22498825)

  • 1. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
    Alvarez T; Miller E; Duska L; Oliva E
    Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
    Cuatrecasas M; Catasus L; Palacios J; Prat J
    Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
    Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
    Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
    Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
    Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
    Koyuncuoglu M; Okyay E; Saatli B; Olgan S; Akin M; Saygili U
    Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
    Semczuk A; Marzec B; Skomra D; Roessner A; Cybulski M; Rechberger T; Schneider-Stock R
    Oncology; 2005; 69(4):317-25. PubMed ID: 16293976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
    Orezzoli JP; Sioletic S; Olawaiye A; Oliva E; del Carmen MG
    Gynecol Oncol; 2009 Jun; 113(3):316-23. PubMed ID: 19345400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
    Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
    Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.
    Geyer JT; López-García MA; Sánchez-Estevez C; Sarrió D; Moreno-Bueno G; Franceschetti I; Palacios J; Oliva E
    Am J Surg Pathol; 2009 Aug; 33(8):1157-63. PubMed ID: 19542870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
    Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
    Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
    Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
    Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
    Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of p53 overexpression in endometrial cancer.
    Ito K; Watanabe K; Nasim S; Sasano H; Sato S; Yajima A; Silverberg SG; Garrett CT
    Cancer Res; 1994 Sep; 54(17):4667-70. PubMed ID: 8062261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry.
    Santacana M; Maiques O; Valls J; Gatius S; Abó AI; López-García MÁ; Mota A; Reventós J; Moreno-Bueno G; Palacios J; Bartosch C; Dolcet X; Matias-Guiu X
    Hum Pathol; 2014 Dec; 45(12):2394-403. PubMed ID: 25282036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endometrioid carcinoma simultaneously involving the uterus and the fallopian tube: a clinicopathologic study of 13 cases.
    Culton LK; Deavers MT; Silva EG; Liu J; Malpica A
    Am J Surg Pathol; 2006 Jul; 30(7):844-9. PubMed ID: 16819326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.
    Morrison C; Zanagnolo V; Ramirez N; Cohn DE; Kelbick N; Copeland L; Maxwell GL; Fowler JM
    J Clin Oncol; 2006 May; 24(15):2376-85. PubMed ID: 16710036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.